Form 4: Applied Therapeutics Director Acquires 350,000 Restricted Stock Units

Leslie D. Funtleyder, Interim CEO and CFO of Applied Therapeutics, acquired 350,000 Restricted Stock Units (RSUs) on March 24, 2025, according to a Form 4 filing.

Summary

• Leslie D. Funtleyder, a director and Interim CEO/CFO of Applied Therapeutics, Inc. (APLT), filed a Form 4 disclosing a transaction.
• On March 24, 2025, Funtleyder acquired 350,000 Restricted Stock Units (RSUs) under the company's 2019 Equity Incentive Plan.
• These RSUs are compensatory and represent a contingent right to receive one share of APLT common stock per RSU.
• Vesting occurs in installments, with one-fourth vesting on March 24, 2026, and the remaining shares vesting monthly over the subsequent 36 months, contingent upon continued service.
• Following the transaction, Funtleyder beneficially owns 740,459 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of RSUs to a key executive is a positive sign of alignment with shareholder interests and incentivizes long-term commitment. There are no immediately negative implications.

Positives

• The acquisition of RSUs by a key executive signals confidence in the company's future.
• The vesting schedule incentivizes continued service and commitment from the executive.

Future Outlook

The vesting schedule of the RSUs suggests an expectation of continued service and contribution from the executive over the next three years.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates a grant of equity compensation to a key executive, which is a common practice in the biotechnology industry to align management's interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation is a standard practice in the biotech industry, often used to attract and retain talent, especially in companies like Applied Therapeutics that are focused on research and development.
• Companies such as BioMarin Pharmaceutical and Vertex Pharmaceuticals also utilize stock options and RSUs as part of their compensation packages for executives and employees.
• The vesting schedule of these RSUs is typical, with vesting occurring over several years to incentivize long-term commitment.

Stakeholder Impact

• Shareholders may view the RSU grant positively as it aligns management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, Applied Therapeutics, APLT, Restricted Stock Units, RSUs, Leslie D. Funtleyder, Beneficial Ownership, Equity Incentive Plan, Director, CEO, CFO